BridgeBio Pharma Inc Director Hannah Valantine Sells 2,915 Shares
On January 16, 2024, Director Hannah Valantine sold 2,915 shares of BridgeBio Pharma Inc (NASDAQ:BBIO), as reported in a recent SEC filing. The transaction was executed at an average price of $37.97 per share, resulting in a total sale amount of approximately $110,652.55.
BridgeBio Pharma Inc is a biotechnology company focused on discovering, developing, and delivering breakthrough medicines for genetic diseases. The company has a diverse portfolio of drug candidates targeting various illnesses, with an emphasis on genetic dermatology, oncology, and cardiology.
Over the past year, the insider has sold a total of 8,745 shares of BridgeBio Pharma Inc and has not made any purchases of the stock. The recent sale by Hannah Valantine continues a trend of insider selling at the company, with a total of 24 insider sells and no insider buys reported over the same period.
Shares of BridgeBio Pharma Inc were trading at $37.97 on the day of the insider's transaction, giving the company a market capitalization of $6.534 billion.
The stock's price-to-GF-Value ratio stands at 20.2, indicating that BridgeBio Pharma Inc is significantly overvalued according to the GF Value. The GF Value is a proprietary intrinsic value estimate from GuruFocus, which takes into account historical trading multiples, a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates from Morningstar analysts.
The insider's recent sale may attract the attention of investors monitoring insider transactions as an indicator of confidence in the company's prospects. It is important to note that insider selling does not always suggest a lack of confidence in the company and can be motivated by various personal or financial reasons.
Investors are encouraged to consider the broader context of the market, the company's performance, and other indicators before making investment decisions.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
